COMMUNIQUÉS West-GlobeNewswire

Valneva publie ses résultats financiers audités et consolidés pour l’exercice 2025
18/03/2026
Chiffre d’affaires de 174,7 millions d’euros, conforme aux prévisions, dont 157,9 millions de ventes de produits Solide position de trésorerie de 109,7 millions d’euros et flexibilité financière renforcée suite au [...]
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
18/03/2026
IPN01203 data to be presented at coveted New Drugs on the Horizon program session, demonstrating early potential of this novel T cell activator to transform care in solid tumors ITGA2 revealed as novel target of Ipsen’s [...]
Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
18/03/2026
Sanofi’s venglusta t earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026 . The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to [...]
CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
18/03/2026
SOUTH SAN FRANCISCO, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a leader in the field of masked, conditionally activated biologics, today announced the pricing of an underwritten [...]
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
18/03/2026
MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
Mesoblast to Host R&D Day on April 8, 2026
18/03/2026
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day on Wednesday, April 8 [...]
DentaBiome Claims Evaluated: 2026 Oral Postbiotic Consumer Warning Report Issued
18/03/2026
A 2026 consumer warning report examining DentaBiome's oral postbiotic formula, how FabM acid-lock and 30-second kitchen method claims relate to published research, the ingredient research context commonly cited in this [...]
MEDVi GLP-1 Weight Loss Claims Evaluated: 2026 Report Examining "Most Trusted Online Medical Care" Positioning, Telehealth Structure, and Regulatory Context
18/03/2026
A 2026 informational evaluation of MEDVi's GLP-1 weight loss program structure, compounded semaglutide and branded Ozempic access pathways, published pricing disclosures, three-entity telehealth model, refund terms, and [...]
Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026
18/03/2026
ROCKVILLE, Md. and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the [...]
NatureGlyco Blood Support Claims Evaluated: The Proven Glyco Care Formula for Healthy Blood Sugar Support
18/03/2026
A 2026 company-issued informational report covering NatureGlyco's product descriptions, ingredient references, pricing, subscription terms, and consumer verification points for adults researching blood sugar support [...]
Blood Sugar Harmony Liquid Drops Ingredients Disclosed: Complete Details Revealed
18/03/2026
SugarHarmony Research has released ingredient reference materials outlining the compounds associated with Blood Sugar Harmony Liquid Drops, citing scientific references and ingredient context as part of its published [...]
Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum
17/03/2026
FRANKFURT AM MAIN, Germany, March 17, 2026 (GLOBE NEWSWIRE) -- Anbio Biotechnology (NASDAQ: NNNN) ("Anbio" or the "Company"), a global diagnostic company in in-vitro diagnostic (IVD) technologies, announced today that [...]
Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026
17/03/2026
Preclinical evidence supports azenosertib ADC combinations as potential promising therapeutic strategies for Triple-Negative Breast Cancer Demonstration of Cyclin E1 protein overexpression as an indicator for poor [...]
Evaxion to present new data at AACR Annual Meeting
17/03/2026
Two abstracts accepted for presentation One abstract on new additional biomarker and immunogenicity data for personalized cancer vaccine EVX-01 Another abstract on the use of Evaxion’s AI-Immunology™ platform in [...]
Enara Bio to Unveil First‑in‑Class DARKFOX‑Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential for Solid Tumor Immunotherapy
17/03/2026
Oxford, UK – March 17, 2026. Enara Bio , a pioneer in Dark Antigen® discovery and bispecific T cell engager innovation, today announced new data to be presented at the American Association for Cancer Research (AACR) [...]
SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference
17/03/2026
- Preclinical data show that SLS009 lowers the apoptotic threshold in AML cells by suppressing critical survival pathways - NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“ [...]
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
17/03/2026
SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today [...]
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting
17/03/2026
Immunocore will present five-year overall survival data for KIMMTRAK during oral presentation at the 2026 AACR meeting (OXFORDSHIRE, England & GAITHERSBURG, Md., & RADNOR, Penn., US, 17 March 2026) Immunocore [...]
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
17/03/2026
WILMINGTON, Del., March 17, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that a poster with preclinical data on the Company’s oral KAT6A [...]

Pages